An article published in the Annals of Internal Medicine estimated that non-adherence resulted in approximately 125,000 deaths and at least 10 percent of hospitalizations, costing US health care system $100 and $289 billion a year.
The article reports that “studies have consistently shown that 20 percent to 30 percent of medication prescriptions are never filled, and that approximately 50 percent of medications for chronic diseases are not taken as prescribed. The review found that for people who do take prescription medications, they only take about half the prescribed doses.
Researchers from Northwestern University found that one-third of kidney transplant patients don’t take their anti-rejection medications. Other studies show that 41 percent of heart attack patients don’t take their blood pressure medications and only 50 percent of children with asthma use their inhalers as prescribed.
In an article in the New York Times, Dr. Bruce Bender, co-director of the Centre for Health Promotion at National Jewish Health in Denver, explained: “When people don’t take the medications prescribed for them, emergency department visits and hospitalizations increase and more people die. Non-adherence is a huge problem, and there’s no one solution because there are many different reasons why it happens.”
State of Arthritis Medications: Some old, some new, all important
The reliable, quick reference arthritis medications guide you need to assist you and your health care team with your therapy conversations.
The JointHealth™ Medications Guide gives you information on the most commonly prescribed medications for inflammatory types of arthritis and osteoarthritis. Medication information for the following diseases is included in this year’s guide: rheumatoid arthritis, ankylosing spondylitis, juvenile arthritis, psoriatic arthritis, systemic lupus erythematosus, vasculitis, osteoarthritis, and osteoporosis.
In this JointHealth™ insight, you will also find:
- An explanation of the naming changes in the different categories of
- Insight into the patient-physician therapy conversation by Cheryl Koehn, Founder and President of Arthritis Consumer Experts
- Updated disease information for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, juvenile arthritis, and lupus
- The latest research on methotrexate and the consumption of alcoholic beverages
Treating rheumatoid arthritis (RA) early and aggressively is vitally important and can help to prevent crippling joint damage. Today specialists recommend a treatment plan that includes education, medication-often a combination of several different types of medication will be used in a person’s treatment plan-social support, appropriate amounts of range-of-motion, cardiovascular and muscle strengthening exercises, rest, vitamins and mineral supplements and a well-balanced diet. Biomarker tests may also help to detect RA and prevent further joint damage.
A checkup appointment at my rheumatologist (doctor who specializes in arthritis) always leads to some interesting discussions. Most of the time I try to “research” a topic beforehand, so that I am armed with the latest background information on whatever are my most pressing concerns at the time. When I launch into my questions (I always have a list written out), I have a better-than-even chance of holding a meaningful conversation with my rheumy. In turn, I get more out of the conversation instead of returning home with questions that even Google cannot answer. Understanding what he is really saying provides me with the sense that I am in control of my ankylosing spondylitis (AS), and not the other way around (AS controlling me?) Continue reading
Photo courtesy of David Castillo Dominici | FreeDigitalPhotos.net
The long-term usage of non-steroidal anti-inflammatories (NSAIDs) has always concerned me. Through the years I have taken different types of NSAIDs for varying periods. These NSAIDs even included (for a short time) VIOXX, which was pulled off the shelves in 2004 after studies confirmed that it increased the risk of heart attack and stroke. For many years I have taken diclofenac, which now researchers also believe carries a high cardiovascular risk, especially for people with a history of heart disease or other risk factors such as diabetes or high cholesterol. Continue reading
Call for patient organization input on certolizumab pegol (Cimzia®) for psoriatic arthritis
Do you have psoriatic arthritis or care for someone who does? We need your valuable input.
The Common Drug Review (CDR) is currently welcoming patients and their caregivers to provide input to patient organizations on the manufacturer’s submission for certolizumab pegol (Cimzia®) for the treatment of psoriatic arthritis (PsA). Certolizumab pegol is indicated for use in combination with methotrexate for reducing signs and symptoms and inhibiting the progression of structural damage as assessed by X-ray, in adult patients with moderately to severely active psoriatic arthritis who have failed one or more disease-modifying anti-rheumatic drugs (DMARDs). Continue reading